Icagen, Inc. Announces Formation of Drug Discovery and Development Expert Panel
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Icagen, Inc. (NASDAQ: ICGN) announced today the formation of a drug discovery and development expert panel with the initial appointment of two distinguished pharmaceutical industry executives. Icagen's drug discovery and development expert panel, which will include individuals from both the pharmaceutical industry and academia, is being formed in order to provide ongoing advice and guidance on key scientific and clinical development issues related to the Company's portfolio of drug discovery and development programs. In addition to the Company's program in sickle cell disease, these programs include ion channel-focused efforts in epilepsy, neuropathic pain, inflammation and attention deficit/hyperactivity disorder. The initial members of this panel from the pharmaceutical industry are Christopher Cimarusti, Ph.D. and Ian Skidmore, Ph.D. The Company expects to announce the appointment of additional members to its drug discovery and development expert panel over the next several weeks.